Yi Larson currently serves as the Chief Financial Officer of LianBio, a global biopharmaceutical company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets.
Previously, she was Executive Vice President and Chief Financial Officer of Turning Point Therapeutics, Inc., a clinical stage precision oncology company. In this role, she oversaw all aspects of the finance and accounting organization, led corporate strategy and business development, helped raise over $1 billion through 3 follow-on offerings, and spearheaded deal-making activities, including the out-licensing of Turning Point’s lead drug candidates for the Chinese market. During her tenure, Yi helped grow Turning Point from $1 billion to $5 billion+ in market cap.
Prior to Turning Point Therapeutics, Ms. Larson was a Managing Director of Healthcare Investment Banking at Goldman Sachs where she worked for over 12 years. She advised senior management teams and boards on a range of strategic and financial matters, successfully executing over 50 deals, including $70 billion in M&A activities and $30 billion in financings.
She has also served as a member of the board of directors of Olema Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, since April 2021. Ms. Larson earned an MBA, concentrated in Finance, from The Wharton School at the University of Pennsylvania. She also earned a master’s degree in Electrical Engineering and Computer Science and a bachelor’s degree in Electrical Engineering, both from the Massachusetts Institute of Technology (MIT).